UBS Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

UBS Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,200	Closed	-$196K	–	11374
2022 Q1	$196K	Buy	+5,200	New	+$206K	﹤0.01%	5389

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

UBS Group's RXDX Position: Q2 2023 in Review

UBS Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 7,244 shares — an estimated $777K sold.

UBS Group first reported a position in RXDX in Q1 2021 and held it in 8 quarters. The position peaked at $3.72M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

UBS Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
UBS Group sold 7,244 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $777K.
UBS Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
UBS Group's Prometheus Biosciences, Inc. Common Stock position peaked at $3.72M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.